A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.

Question

Six frontier AI models put this at 22% by 25 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

22% — the median of 6 frontier models, resolving by 2036-10-25.

Answer

Gemini (Google): 37% — Success hinges on solving microvascular thrombosis and metabolic perfusion in human-scale bioprinted tissue to win FDA IND clearance. Simple bioprinted tissues have reached humans, but full organs require hierarchical microvasculature that degrades within hours in vivo. Companies like United Therapeutics have 2028-2030 lung trial targets, but regulatory bars for vital solid organs trigger chronic delays. Long-term graft survival without microclotting in non-human primate trials by 2028 would push probability above 60%.

Answer

Claude (Anthropic): 22% — Hinges on whether vascularized bioprinted organ constructs clear preclinical/regulatory hurdles for first-in-human trials by 2032. Current bioprinting progress (e.g., kidney/liver tissue patches, vascularized skin grafts) is advancing but full solid organs with robust perfusable vasculature remain… Regulatory pathways (FDA/EMA) for novel tissue-engineered organs require extensive preclinical safety/efficacy data, typically adding 3-5+ years after proof-of-concept. Simpler vascularized constructs (partial organs, patches) may qualify before 2032 if resolution criteria are lenient, which raises probability somewhat above a strict…

Answer

GPT (OpenAI): 41% — The bottleneck is proving durable perfusion, safety, and organ-level function well enough for an FDA/EMA first-in-human IND. No vascularized, 3D-bioprinted solid organ has yet reached patients; most human work remains sheets, grafts, or non-printed constructs. A sponsor must complete large-animal durability, GMP manufacturing, and regulator-cleared IND work before the 2032 cutoff. A kidney, liver, or cardiac graft with sustained primate function would sharply raise the odds; 2026-31 is a short translational window.

Answer

Grok (xAI): 14% — A printed vascularized solid organ must finish large-animal function data and gain trial authorization by end-2031. United Therapeutics, Wake Forest or similar groups need multi-year GLP animal survival data before any IND/CTA filing. Complex organ first-in-human timelines (xeno kidneys, tissue-engineered bladders) historically run 15-25 years from proof-of-concept. A 2027-28 large-animal printed kidney or liver with months of function would be the main upward revision trigger.

Answer

DeepSeek (DeepSeek): 22% — Whether any bioprinted solid organ with perfusable vasculature clears FDA to start human trials within roughly nine years. Only a handful of groups (United Therapeutics, Organovo, Prellis, academic labs) are near this; United Therapeutics targets first human lung transplant trials around… Before any trial, they need a reproducible organ that perfuses and survives in large animals; no bioprinted solid organ has yet shown durable function in a primate model. Base rate for novel organ-engineering platforms reaching first-in-human within a decade is low, but vascularized kidney/liver scaffolds are already in animal work, so…

Answer

Qwen (Alibaba): 5% — No vascularized bioprinted solid organ has cleared large-animal efficacy; the IND-to-first-patient pipeline alone takes 3–5 years. As of 2026, no group has published a bioprinted solid organ with perfusable vasculature surviving in a large-animal model long enough to justify an IND filing. FDA's CBER would require GLP toxicology and biodistribution data in a relevant species before allowing a Phase I, adding ~2–3 years after any breakthrough. The one development that would raise this sharply: a pre-IND meeting disclosure or published large-animal survival data from a group like United Therapeutics, Prellis…

A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.

A fully lab-grown solid human organ is successfully transplanted into a patient before 2035.

Standard clinical turnaround for an ex vivo autologous gene editing therapy falls below 14 days before 2030.

An in vivo CRISPR gene editing therapy receives standard FDA approval before 2028.

Human germline gene editing results in a live birth before 2030.